<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01361841</url>
  </required_header>
  <id_info>
    <org_study_id>CHUS-09-184</org_study_id>
    <nct_id>NCT01361841</nct_id>
  </id_info>
  <brief_title>Effects of Latanoprost, Bimatoprost and Travoprost in Patients With Latanoprost-resistant Glaucoma</brief_title>
  <official_title>Effects of Latanoprost, Bimatoprost and Travoprost in Patients With Latanoprost-resistant Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intraocular pressure (IOP) is considered to be the main risk factor for progression of&#xD;
      glaucoma and therefore the main target of therapy. Pharmacologic treatment of glaucoma has&#xD;
      changed considerably during the last decades due to the introduction of prostaglandin&#xD;
      analogues. Three of these are commonly used in North America: latanoprost (Latanoprost T,&#xD;
      Pfizer), Travoprost (Travatan TM, Alcon) and bimatoprost (Lumigan TM, Allergan).&#xD;
&#xD;
      There have been several studies to evaluate their effectiveness. The three seem to be&#xD;
      equivalent, according to the only study that has compared the molecules. Latanoprost is&#xD;
      employed initially, due to its paucity of side effects when compared to the other two&#xD;
      analogues. However, if it is not effective, several studies ahve shown that a result is&#xD;
      possible using either travoprost or bimatoprost. No study has been conducted to date&#xD;
      systematically comparing the three molecules in cases of resistance to latanoprost. In&#xD;
      actuality, the investigators patients will receive treatment identical to current practice&#xD;
      with the exception of the group continuing with latanoprost. Several studies confirm the&#xD;
      benefit of changing prostaglandin analogues if the first has not signficantly decreased the&#xD;
      IOP (Palmberg et al. 2004). Each prostaglandin has unique properties which may cause the&#xD;
      mechanism of action to vary slightly among patients. (cf. Pharmacological Aspects)&#xD;
&#xD;
      The goal of the study is thus to evaluate the efficaciousness of latanoprost, bimatoprost and&#xD;
      travoprost in their IOP-lowering capacity in patients who do not initially respond to&#xD;
      latanoprost.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research question:&#xD;
&#xD;
      What is the effectiveness of latanoprost, bimatoprost and travoprost in patients whose&#xD;
      intraocular pressure does not decrease by at least 20% while undergoing treatment with&#xD;
      latanoprost ?&#xD;
&#xD;
      Secondary questions:&#xD;
&#xD;
      1- What is the percentage of glaucoma patients who are resistant to latanoprost ? 2- Which&#xD;
      prostaglandin is the most effective in decreasing intraocular pressure in cases of resistance&#xD;
      to latanoprost ?&#xD;
&#xD;
      Research Project Goals :&#xD;
&#xD;
      Evaluation of the effectiveness of latanoprost, bimatoprost and travoprost in patients in&#xD;
      whom latanoprost does not decrease the intraocular pressure by at least 20%. The&#xD;
      effectiveness of the three prostaglandins will be determined by the IOP : the treatment&#xD;
      should at least effect a 20% decrease from baseline (IOP measured at time of recruitment),&#xD;
      with the ultimate aim of attaining the target IOP, which varies depending on the patient.&#xD;
      Target IOP is based on the severity of optic nerve damage as well as baseline IOP.&#xD;
&#xD;
      Determine the percentage of patients resistant to prostaglandins. Patients who have not&#xD;
      responded (as measured by IOP decrease) to more than 2 prostaglandins will be considered&#xD;
      resistant to this category of hypotensive medications.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      Randomised, open label.&#xD;
&#xD;
      Study duration:&#xD;
&#xD;
      Approximately two years.&#xD;
&#xD;
      POPULATION:&#xD;
&#xD;
      The target population consists of open angle glaucoma patients, or patients with ocular&#xD;
      hypertension with an IOP greater than 21 mmHg and who have never undergone treatment for&#xD;
      glaucoma. Patients must be 18 years or older, capable of giving informed consent in written&#xD;
      form.&#xD;
&#xD;
      Sampling&#xD;
&#xD;
        -  Candidates will be selected from the patient population of the ophthalmology clinic of&#xD;
           the CHUS hotel-Dieu or from the private practice of Dr. Blondeau&#xD;
&#xD;
        -  The patients will all be treated with latanoprost for approximately 6 weeks, after which&#xD;
           only those who have not experienced at least a 20% decrease in their initial IOP and who&#xD;
           are eligible will be invited to participate in the study.&#xD;
&#xD;
      Sample size - The sample size estimate is based on the need to obtain a significant decrease&#xD;
      from baseline IOP at 6 weeks, 2 months and 6 months. Estimating a maximum IOP variation of 2&#xD;
      mmHg with a standard deviation of +/- 2 mmHg, the necessary sample size to power the study&#xD;
      (90% with a p &lt; 0.05 using a paired-samples Student T test) is about 47 patients per group.&#xD;
&#xD;
      Methods of randomization and sample make-up:&#xD;
&#xD;
      The study will be a randomized and comparative trial taking place over a period of 12 months.&#xD;
      Patients will be distributed by random lots of 6 (ACBCAB, etc) into 3 different groups after&#xD;
      a documented non-response (IOP decrease of less than 20%) to latanoprost. Group 1 will remain&#xD;
      on Latanoprost 0.005%, Group 2 will switch to travoprost 0.004% and Group 3 will switch to&#xD;
      bimatoprost 0.03%. The dose of each medication will be 1 drop daily HS, which is the usual&#xD;
      dose in ophthalmological practice and in the scientific literature.&#xD;
&#xD;
      Intraocular pressure will be measured in the same manner for all patients by applanation&#xD;
      tonometry.&#xD;
&#xD;
      Thus, for each study participant:&#xD;
&#xD;
      Time of IOP measurement IOP value (mmHg) At time of recruitment 6 weeks after 2 months after&#xD;
      6 months after&#xD;
&#xD;
      * Therefore, 3 groups of patients will have the same measurements taken.&#xD;
&#xD;
      Stages of the study:&#xD;
&#xD;
        1. Patient recruitment:&#xD;
&#xD;
           - Diagnosis of glaucoma de novo in the outpatient clinic or Dr. Blondeau's office.&#xD;
&#xD;
           - Patients will be informed about the possibility of resistance to a treatment of 6&#xD;
           weeks with latanoprost, as well as to its possible benefit. The patient will receive a&#xD;
           consent form, consisting of an explanation of the study including potential side effects&#xD;
           of the medications. Patients will be able to take the time to thoroughly read the&#xD;
           document and to decide whether they wish to participate in the study.&#xD;
&#xD;
        2. Consent:&#xD;
&#xD;
           - Informed consent will be obtained by ophthalmologist Dr. Pierre Blondeau or the&#xD;
           resident in ophthalmology, Zineb Ghali, PGY IV, who will offer clarification and&#xD;
           explanation to the potential participants if necessary.&#xD;
&#xD;
        3. Trial Design:&#xD;
&#xD;
      1. Patients with a diagnosis of primary open-angle glaucoma (POAG) or ocular hypertension&#xD;
      (OH) but who have never received treatment will be recruited.&#xD;
&#xD;
      2. Recruited patients will be treated for 6 weeks with latanoprost. This corresponds to the&#xD;
      time necessary for the molecule to block the all prostaglandin receptors, thus allowing for&#xD;
      maximum IOP-lowering potential. This period of time was determined by the pharmaceutical&#xD;
      company that created the molecule and is used by all studies involving the molecule.&#xD;
&#xD;
      3. Patients who have not experienced a decrease of at least 20% of their baseline IOP and who&#xD;
      consent to participate will be distributed into 3 different groups (recruitment step). Group&#xD;
      1 patients will continue to receive latanoprost 0.005%, 1 drop daily HS. The two other groups&#xD;
      will receive either bimatoprost 0.03% or travoprost 0.004%, 1 drop daily HS. Patients will&#xD;
      continue to be treated for 4 weeks. Patients will receive instructions regarding medication&#xD;
      administration and compliance. The medication will be administered every 24 hours between&#xD;
      20:00 and 22:00. No other IOP-lowering medication will be permitted.&#xD;
&#xD;
      4. Patients with less than 20% response to initial treatment with latanoprost will be&#xD;
      randomised into 3 groups corresponding to one of the prostaglandin analogues. IOP will be&#xD;
      remeasured after 6 weeks in order to evaluate response to the medication. We consider that a&#xD;
      documented response to treatment consists of a significant decrease in IOP as measured by the&#xD;
      t-test. If the IOP has not decreased by at least 20% after 1 month of treatment with the&#xD;
      various prostaglandins, the patient will be excluded from the study, treated with another&#xD;
      class of hypotensive agent, and receive standard follow-up.&#xD;
&#xD;
      Security measures:&#xD;
&#xD;
      The researchers will monitor for possible side effects and other potential problems. To this&#xD;
      effect, an auxiliary researcher (not yet recruited) as well as a resident in ophthalmology&#xD;
      (Zineb Ghali) will be available 24 hours a day to address medication side effects or&#xD;
      unexpected symptoms. If immediate follow-up is required and the patient makes contact during&#xD;
      business hours, the research team will immediately see the patient. If the patient contacts&#xD;
      the auxiliary researcher or the resident outside of business hours, he or she will be&#xD;
      immediately referred to one of the ophthalmology residents on call at the hotel Dieu hospital&#xD;
      Emergency Department. If necessary, one of the two physician researchers will be available to&#xD;
      meet with the patient in question.&#xD;
&#xD;
      This ensures that any adverse reaction will be rapidly treated by the research team. If a&#xD;
      physician observes undesirable side effects that are attributable to the medication, he or&#xD;
      she has the duty to discontinue treatment as well as the subject's participation in the&#xD;
      study. In this case, the physician will ensure continuity of care via another form of&#xD;
      treatment in order to ensure the patient's recovery.&#xD;
&#xD;
      Principal dependent variable:&#xD;
&#xD;
      Intraocular pressure shall be measured with a Goldmann tonometer.&#xD;
&#xD;
      A drop of fluorescein sodium and benoxinate hydrochloride, USP (0.25%/0.4%) will be instilled&#xD;
      in the patient's eyes, after which baseline IOP will be measured by Goldmann tonometry. The&#xD;
      inter-measurement variability is +/- 2mmHg.&#xD;
&#xD;
      Secondary variables:&#xD;
&#xD;
        -  Patient age: quantitative&#xD;
&#xD;
        -  Patient sex: qualitative&#xD;
&#xD;
        -  Patient race: qualitative&#xD;
&#xD;
        -  Side effects&#xD;
&#xD;
           4- Results analysis&#xD;
&#xD;
      Homogeneity of groups in terms of social demographics will be verified via one-way analysis&#xD;
      of variance (ANOVA) with Turkey's correction for continuous variables and a chi-square or&#xD;
      Fisher's exact test for categorical variables. Values discovered to be significant will be&#xD;
      expressed in the following format: obtained value as well as confidence interval, in order to&#xD;
      highlight the impact of the particular treatment&#xD;
&#xD;
      Two-way crossed ANOVA will be used to compare data collected during follow-up with different&#xD;
      ophthalmological exams, notably the IOP. We will calculate the impact for each period of&#xD;
      follow-up.&#xD;
&#xD;
      The incidence of individual side effects will be summarized and compared with a chi-square&#xD;
      test. Emphasis will be placed on the degree of severity of symptoms caused by the medications&#xD;
      used. The examined side effects will be those that occur most frequently and are of ocular&#xD;
      nature.&#xD;
&#xD;
      There is no interim analysis included in this research project. All statistical tests will&#xD;
      consider a p-value of less than 0.05 to be statistically significant, i.e. all results will&#xD;
      be considered statistically significant at the 5% level.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>intraocular pressure</measure>
    <time_frame>2 years</time_frame>
    <description>A drop of fluorescein sodium and benoxinate hydrochloride, USP (0.25%/0.4%) will be instilled in the patient's eyes, after which baseline IOP will be measured by Goldmann tonometry. The inter-measurement variability is +/- 2mmHg.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">141</enrollment>
  <condition>Ocular Hypertension</condition>
  <condition>Primary Glaucoma</condition>
  <arm_group>
    <arm_group_label>ophtalmic solution,</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Travoprost, latanoprost and bimatoprost, ophthalmic solution are topical medications used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. they are synthetic prostaglandin F 2Î± analogue (and prodrug for bimatoprost) that works by increasing the outflow of aqueous fluid from the eyes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost, bimatoprost, travoprost</intervention_name>
    <description>topic drops, once a day at bedtime, for years</description>
    <arm_group_label>ophtalmic solution,</arm_group_label>
    <other_name>Xalatan</other_name>
    <other_name>Lumigan</other_name>
    <other_name>Travatan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>travoprost, latanoprost and bimatoprost</intervention_name>
    <description>one drop once a day for life</description>
    <arm_group_label>ophtalmic solution,</arm_group_label>
    <other_name>Travatan</other_name>
    <other_name>Xalatan</other_name>
    <other_name>Lumigan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with ocular hypertension or primary open-angle glaucoma who have&#xD;
             never received treatment.&#xD;
&#xD;
          -  Age 18 or older and able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with intraocular inflammation of any etiology&#xD;
&#xD;
          -  Patients with advanced glaucoma, defined by severe optic nerve damage and/or visual&#xD;
             field deficit.&#xD;
&#xD;
          -  Patients having had intraocular surgery in the last 4 weeks&#xD;
&#xD;
          -  Patients undergoing treatment with ophthalmic solution of any kind&#xD;
&#xD;
          -  Patients unable to give informed consent to participate in the research&#xD;
             project,including those suffering from psychiatric illness resulting in impaired&#xD;
             judgement&#xD;
&#xD;
          -  Monophthalmia or anophthalmia&#xD;
&#xD;
          -  Pregnant or nursing patients&#xD;
&#xD;
          -  Patients status post ocular surgery, with the exception of cataract extraction surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Blondeau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre hospitalier de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre PB Blondeau, MD</last_name>
      <phone>1 (819) 346 1110</phone>
      <phone_ext>28008</phone_ext>
      <email>pierre.blondeau@videotron.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <study_first_submitted>May 25, 2011</study_first_submitted>
  <study_first_submitted_qc>May 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2011</study_first_posted>
  <last_update_submitted>May 26, 2011</last_update_submitted>
  <last_update_submitted_qc>May 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Centre Hostitalier Universitaire de Sherbrooke</name_title>
    <organization>CHUS</organization>
  </responsible_party>
  <keyword>Latanoprost</keyword>
  <keyword>bimatoprost</keyword>
  <keyword>travoprost</keyword>
  <keyword>non responders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bimatoprost</mesh_term>
    <mesh_term>Travoprost</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

